ArticleScience advances2022
Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 124 citations in OpenAlex.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Encapsulating GSH/NQO1-responsive SN38 prodrug micelles with Timosaponin AIII-based multifunctional liposomes for tumor-targeted chemotherapy.International journal of pharmaceutics: X · 2026Article
- Complement-inflammation inhibition via stealth nanomedicine for mild thermo-responsive postoperative on-demand pain management.Materials today. Bio · 2026Article
- Dual-targeted liposomes delivering ginsenoside CK attenuate cerebral ischemia-reperfusion injury by suppressing PANoptosis via O-GlcNAcylation of RIPK1/RIPK3.Journal of ginseng research · 2026Article
- A conserved germanicol synthase lineage and a single-residue switch controlling triterpene scaffold divergence in Panax.Plant cell reports · 2026Article
- Ginsenoside Rh2-modified liposomes for targeted delivery of Puerarin alleviate brain ischemia-reperfusion injury.Drug delivery and translational research · 2026Article
- Ginsenoside-Mediated Ferroptosis Regulation: Bidirectional Effects and Therapeutic Potential in Diseases.International journal of molecular sciences · 2026Review
- Research Progress on Anticancer Mechanism of Ginsenoside Regulating Tumor Microenvironment.Current issues in molecular biology · 2026Review
- Ginsenoside Rg5 inhibits colorectal cancer, at least partially by blocking the lysosomal degradation of colorectal cancer cells.Scientific reports · 2026Article
- Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacyMaterials today. Bio · 2026Article
- Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism.Journal of translational medicine · 2026Article
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- Dual-Pronged Lipid Nanocarriers Promote Immunotherapy for TNBC by Inducing Immunogenic Cell Death and Activating Lymphoid Immune Cells.Research (Washington, D.C.) · 2026Article
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Inhalable Herbal Nano-Liposomes Co-Delivering Astragaloside IV and Polyphyllin VII Reprogram Immunosuppressive Microenvironment To Overcome Anti-PD-1 Resistance in NSCLC.Biological procedures online · 2025Article
- Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity.Journal of nanobiotechnology · 2025Article
- Prediction of Lung Cancer Metastasis Risk Based on Single-Cell Metabolic Profiling of Circulating Tumor Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer.Materials today. Bio · 2025Article
- Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Bridging the Gap in Breast Cancer Dormancy: Models, Mechanisms, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited circulating tumor cells (CTCs) capturing efficiency and lack of regulation capability on CTC-supportive metastatic niches (MNs) are two main obstacles hampering the clinical translation of conventional liposomes for the treatment of metastatic breast cancers. Traditional delivery strategies, such as ligand modification and immune modulator co-encapsulation for nanocarriers, are inefficient and laborious. Here, a multifunctional Rg3 liposome loading with docetaxel (Rg3-Lp/DTX) was developed, in which Rg3 was proved to intersperse in the phospholipid bilayer and exposed its glycosyl on the liposome surface. Therefore, it exhibited much higher CTC-capturing efficiency via interaction with glucose transporter 1 (Glut1) overexpressed on CTCs. After reaching the lungs with CTCs, Rg3 inhibited the formation of MNs by reversing the immunosuppressive microenvironment. Together, Rg3-Lp/DTX exhibited excellent metastasis inhibition capacity by CTC ("seeds") neutralization and MN ("soil") inhibition. The strategy has great clinical translation prospects for antimetastasis treatment with enhanced therapeutic efficacy and simple preparation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.